In Brief
This article was originally published in The Rose Sheet
Executive Summary
Under an amendment to the FDA Safety and Innovation Act, which passed the U.S. Senate May 24, there will be no further delays in implementation of FDA’s final rule for sunscreen testing and labeling. More news in brief.
You may also be interested in...
In Brief
FDA Commissioner Hamburg is under congressional pressure to enact agency’s new sunscreen rules this summer rather than delaying them until December. In a May 17 letter, six senators say the delay allows companies to carry on “deceptive practices.”
Pallone, Pitts Committed To Cosmetics Legislation In “This Congress”
During a markup of an FDA user-fee bill, legislators from both sides of the aisle affirmed their intent to tackle cosmetics regulation in a separate, stand-alone bill later this year. The user-fee bill omitted a section that was in place previously to implement cosmetics user fees.
Toxic Substances Act Vote Could Come Soon – Lautenberg
Legislators, industry and others shared their views on updating the Toxic Substances Control Act at a Nov. 17 hearing of the Senate Environment and Public Works Committee’s Subcommittee on Superfund, Toxics and Environmental Health.